Loading...

NMRA NEUMORA THERAPEUTICS INC Company Mergers 8-K Filing

NMR

NMR

NEUMORA THERAPEUTICS INC

(NMRA)

2025 8-K

Financial Results Announcement

Investor Presentation

Investor Presentation

Positive Study Results

Stock Conversion Notice

Financial Results Update

Phase 1 Study Initiated

Positive Drug Data

Financial Statements

Delisting due to Non-Compli...

Financial Statements

Financial Results

Leadership Changes

Leadership Changes

Investor Presentation

Q3 Financial Results

External Links:

Neumora Therapeutics, Inc. reported positive preclinical data on October 27, 2025, showing that its drug NMRA-215 achieved a weight loss of 19% as a standalone treatment and 26% when combined with semaglutide in mouse studies.

AI Assistant

NEUMORA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.